Výsledky vyhledávání - "Mustafa ÖZGÜROĞLU"

Akademický článek

Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC

Autor: Johan F. Vansteenkiste, MD, PhD, Jarushka Naidoo, MB, BCH, MHS, Corinne Faivre-Finn, MD, PhD, Mustafa Özgüroğlu, MD, Augusto Villegas, MD, Davey Daniel, MD, Shuji Murakami, MD, Rina Hui, M.B.B.S., PhD, Ki Hyeong Lee, MD, Byoung Chul Cho, MD, PhD, Kaoru Kubota, MD, PhD, Helen Broadhurst, MSc, Catherine Wadsworth, BVSc, Michael Newton, PharmD, Piruntha Thiyagarajah, MD, Scott J. Antonia, MD

Publikováno v: JTO Clinical and Research Reports, Vol 5, Iss 3, Pp 100638- (2024)

Introduction: In the placebo-controlled, phase 3 PACIFIC trial, durvalumab significantly prolonged progression-free survival (PFS) (p < 0.0001) and overall survival (OS) (p = 0.00251) in patients with unresectable stage III NSCLC and no progression a

Externí odkaz: https://doaj.org/article/86197b668ce247a6aed1dbb164a76e9d

Zobrazit plný text záznamu

Akademický článek

An Open-Label, Multinational, Multicenter, Phase IIIb Study with Subcutaneous Administration of Trastuzumab in Patients with HER2-Positive Early Breast Cancer to Evaluate Patient Satisfaction

Autor: İrfan Cicin, Mohammed Oukkal, Hassen Mahfouf, Amel Mezlini, Blaha Larbaoui, Slim Ben Ahmed, Hassan Errihani, Khalid Alsaleh, Rhizlane Belbaraka, Perran Fulden Yumuk, Burce Goktas, Mustafa Özgüroğlu

Publikováno v: European Journal of Breast Health, Vol 18, Iss 1, Pp 63-73 (2022)

Objective:This study was designed to investigate treatment satisfaction in patients and Health Care Professionals (HCP) and to evaluate the safety and tolerability of subcutaneous (SC) trastuzumab in patients with human epidermal growth factor recept

Externí odkaz: https://doaj.org/article/44aa8ae6d88d49109eadb32a73987363

Zobrazit plný text záznamu

Akademický článek

Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report

Autor: Yuanbin Chen, MD, PhD, Luis Paz-Ares, MD, PhD, Niels Reinmuth, MD, PhD, Marina Chiara Garassino, MD, Galina Statsenko, MD, Maximilian J. Hochmair, MD, Mustafa Özgüroğlu, MD, PhD, Francesco Verderame, MD, Libor Havel, MD, György Losonczy, MD, PhD, Nikolay V. Conev, MD, PhD, Katsuyuki Hotta, MD, PhD, MPH, Jun Ho Ji, MD, PhD, Stuart Spencer, MSc, Tapashi Dalvi, PhD, MPH, Haiyi Jiang, MD, Jonathan W. Goldman, MD

Publikováno v: JTO Clinical and Research Reports, Vol 3, Iss 6, Pp 100330- (2022)

Introduction: In the phase 3 study involving the use of durvalumab with or without tremelimumab in combination with platinum-based chemotherapy in untreated extensive-stage SCLC (CASPIAN study), first-line durvalumab plus platinum-etoposide (EP) sign

Externí odkaz: https://doaj.org/article/1c079ba625de443f80bdb5548364cf07

Zobrazit plný text záznamu

Akademický článek

UNUSUAL PRESENTATION OF CERVICAL CARCINOMA METASTASIS TO THE BREAST: A CASE REPORT AND REVIEW OF THE LITERATURE

Autor: Özlem Yetmen, Didem Çolpan Öksüz, Fuat Demirkıran, Mustafa Özgüroğlu, Zerrin Calay, Gülyüz Atkovar, İsmet Sahinler

Publikováno v: European Journal of Breast Health, Vol 8, Iss 2, Pp 92-96 (2012)

Background:Metastasis to the breast from cervical carcinoma is rarely seen.Case:A 34-year-old woman with FIGO stage III-B cervical carcinoma received potentially curative chemoradiotherapy following which, there was residual tumor. One month later, s

Externí odkaz: https://doaj.org/article/aaf7fe6011614edeb607fe861c3380fc

Zobrazit plný text záznamu

Five-Year Survival Outcomes From the PACIFIC Trial

Publikováno v: Spigel, D R, Faivre-Finn, C, Gray, J E, Vicente, D, Planchard, D, Paz-Ares, L, Vansteenkiste, J F, Garassino, M C, Hui, R, Quantin, X, Rimner, A, Wu, Y-L, Özgüroğlu, M, Lee, K H, Kato, T, de Wit, M, Kurata, T, Reck, M, Cho, B C, Senan, S, Naidoo, J, Mann, H, Newton, M, Thiyagarajah, P & Antonia, S J 2022, ' Five-Year Survival Outcomes From the PACIFIC Trial : Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 40, no. 12, pp. 1301-1311 . https://doi.org/10.1200/JCO.21.01308
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 40(12), 1301-1311. American Society of Clinical Oncology
Spigel, D R, Faivre-Finn, C, Gray, J E, Vicente, D, Planchard, D, Paz-Ares, L, Vansteenkiste, J F, Garassino, M C, Hui, R, Quantin, X, Rimner, A, Wu, Y-L, Özgüroğlu, M, Lee, K H, Kato, T, Wit, M D, Kurata, T, Reck, M, Cho, B C, Senan, S, Naidoo, J, Mann, H, Newton, M, Thiyagarajah, P & Antonia, S J 2022, ' Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer ', Journal of Clinical Oncology . https://doi.org/10.1200/JCO.21.01308

PURPOSE The phase III PACIFIC trial compared durvalumab with placebo in patients with unresectable, stage III non–small-cell lung cancer and no disease progression after concurrent chemoradiotherapy. Consolidation durvalumab was associated with sig

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d7eafbcbb57f61fad4fd50892336d30
https://doi.org/10.1200/jco.21.01308

Zobrazit plný text záznamu

Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO)

Autor: Benjamin Levy, Fabrice Barlesi, Luis Paz-Ares, Jaafar Bennouna, Mustafa Erman, Enriqueta Felip, Dolores Isla, Hye Ryun Kim, Sang-We Kim, Jeannick Madelaine, Olivier Molinier, Mustafa Özgüroğlu, Delvys Rodríguez Abreu, Abidemi Adeniji, Robert M. Lorence, Isabelle Voccia, Michael J. Chisamore, Jonathan W. Riess

Publikováno v: Scientia
LUNG CANCER
LUNG CANCER, 2022, 166, pp.107-113. ⟨10.1016/j.lungcan.2022.01.023⟩

Afatinib; Carcinoma, Squamous Cell; Pembrolizumab Afatinib; Carcinoma de células escamosas; Pembrolizumab Afatinib; Carcinoma de cèl·lules escamoses; Pembrolizumab Introduction Afatinib and pembrolizumab have separately shown survival benefit in p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a6154ee0d6f5200eddf5a3d35311b7f
https://doi.org/10.1016/j.lungcan.2022.01.023

Zobrazit plný text záznamu

Impact of abiraterone acetate plus prednisone in patients with castration-sensitive prostate cancer and visceral metastases over four years of follow-up: A post-hoc exploratory analysis of the LATITUDE study

Autor: Giulia Baciarello, Mustafa Özgüroğlu, Suneel Mundle, Gerhard Leitz, Ute Richarz, Peter Hu, Susan Feyerabend, Nobuaki Matsubara, Kim N. Chi, Karim Fizazi

Publikováno v: European Journal of Cancer. 162:56-64

A post-hoc analysis of the phase-3 LATITUDE study assessed the impact of abiraterone acetate plus prednisone (AA+P) on overall survival (OS) and radiographic progression-free survival (rPFS) in men with metastatic castration-sensitive prostate cancer

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3853b9f6e939946bffe49081872bf1e
https://doi.org/10.1016/j.ejca.2021.11.026

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání